Yaroslau Compta Hirnyj

Parkinson’s disease and other neurodegenerative movement disorders: clinical and experimental research

ORCID Research Profile

Yaroslau Compta Hirnyj

Position: Adjunct medical lecturer

ycompta (at) ub.edu

Research team




Maria J Martí (coordinator of the Parkinson Unit of the Hospital Clínic de Barcelona, medical associate professor UB)


Eduard Tolosa (Emeritus professor UB)


Francesc Valldeoriola ( coordinator of the surgical programme for movement disorders of the Hospital Clínic de Barcelona, medical associate professor UB)


Esteban Muñoz (coordinador of CSUR ataxia and spastic paraplegia of the Hospital Clínic de Barcelona, medical associate professor UB)


Almudena Sánchez (member of the movement disorders and responsible of the Parkinson consulting room prodrome of the Hospital Clínic de Barcelona)


Yaroslau Compta (medical associate professor UB, representative of MDS endorsed PSP study group, Hospital Clínic de Barcelona)


Parkinson-specialised nurse


Ana Cámara (Hospital Clínic de Barcelona)


Senior researchers


Mario Ezquerra (Investigador IDIBAPS)


Rubén Fernández (JIN)


Post-doc researcher


Marta Pulido (FIS)


Lab technician


Manel Fernández (FCRB i CIBERNED)


Clinical trials coordinator


Pilar Santacruz (FCRB)


Clinical trials researcher


Lluís Planellas (FCRB)


Pre-doc researchers


Sandra Pérez-Soriano (PhD4MD)


Cèlia Painous (Río Hortega)




Laura Maragall (FCRB i CIBERNED)

Contact details


Dr. Compta Hirnyj, Yaroslau

Department of Medicine

Faculty of Medicine, Casanova 143

08036 Barcelona (Spain)

ycompta (at) ub.edu

The Parkinson’s disease & movement disorders research team to which Yaroslau Compta belongs has consolidated a line of research on cerebrospinal fluid (CSF) biomarkers in Parkinson’s diseae (PD) dementia and established a correlation between neurochemical Alzheimer and imaging markers in Parkinson disease.


 Work is ongoing in both PD and atypical parkinsonisms to characterize other molecular and imaging biomarkers. Yaroslau Compta has participated in the definition of the new MDS-endorsed diagnostic criteria for progressive supranuclear palsy (PSP). 


The research group has also characterized the non motor symptoms of LRRK2- Parkinson disease and created a repository of biological material of subjects with LRRK2 associated Parkinson disease and their asymptomatic relatives. In a large post-mortem study they have documented multiorgan involvement with alpha synuclein aggregates in Parkinson disease and described for the first time alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonisma probable preclinical marker of Parkinson disease They characterized the non motor symptoms of Parkinson disease in a cohort of 100 cases and defined premotor symptoms predictors of parkinsonism.

Research Interest


Development of translational research projects that aim at taking clinical observations to the lab and the other way around, with a view to eventually improving the diagnosis and treatment of neurodegenerative diseases.

Current Research Line


  •  Development of new CSF biomarkers of neurodegenerative parkinsonisms: detection of aggregating proteins by means of ELISA and new techniques such as RTQuIC, determination of other markers such as coenzyme Q10 or cytokines using multiplex technologies. 
  •  Clinical, genetic, imaging and clinico-pathological correlation studies in atypical parkinsonisms, chiefly tauopathies such as PSP and corticobasal degenerations, both as single-centre and in international multicentric studies. 
  •  Clinical, imaging and genetic characterization of the prodromal phase of both genetic (LRRK2) and sporadic (hyposmia, REM sleep behaviour disorder) forms of Parkinson disease.
  • Generation of IPSC-derived dopaminergic neurons by reprogramming of idiopathic and genetic Parkinson’s disease patient skin fibroblasts. Molecular characterization and elucidation of underlying pathophysiologic mechanisms.



  • Disease / disorder characterization: Endophenotypification studies
  • Assessment of new treatments: Clinical trials, non-dopa agents
  • Methods for diagnostic: Cerebrospinal fluid (CSF) and imaging biomarkers
  • Clinical data: Collaborative clinical registries
  • Development of new tools / technologies / computational methods: Implement new CSF (RTQuIC) and PET (foreseeably in the future tau and eventually alpha-synuclein) markers

Highlighted Publications


Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s diseaseMov Disord. 2009 Nov 15;24(15):2203-10.  


Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A, Muñoz E, Valldeoriola F, Casamitjana R, Ríos J, Marti MJ. Cerebrospinal hypocretindaytime sleepiness and sleep architecture in Parkinson’s disease dementiaBrain. 2009 Dec;132(Pt12):3308-17.  


Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementiawhich is more importantBrain. 2011 May;134(Pt 5):1493-1505.  


Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Cámara A, Cheshire P, Williams DR, Lees AJ, de Silva R. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three– and fourrepeat tau isoforms in tauopathies. J Neurochem. 2012 Nov;123(3):396-405.  


Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, Cámara A, Buongiorno M, Fernández M, Pont-Sunyer C, Martí MJ. Combined dementiarisk biomarkers in Parkinson’s disease: a prospective longitudinal studyParkinsonism Relat Disord. 2013 Aug;19(8):717-24.  


Compta Y, Valente T, Saura J, Segura B, Iranzo Á, Serradell M, Junqué C, Tolosa E, Valldeoriola F, Muñoz E, Santamaria J, Cámara A, Fernández M, Fortea J, Buongiorno M, Molinuevo JL, Bargalló N, Martí MJ. Correlates of cerebrospinal fluid levels of oligomeric– and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J Neurol. 2015 Feb;262(2):294-306.  


Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F, Ríos J, Ramírez I, García JR, Soler M, Cámara A, Fernández M, Basora M, Salazar F, SanchezEtayo G, Valldeoriola F, Barrio JR, Marti MJ. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1. J Alzheimers Dis. 2017;55(3):1261-1272.  


Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Societyendorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsyThe movement disorder society criteriaMov Disord. 2017 Jun;32(6):853-864.  


Compta Y, Giraldo DM, Muñoz E, Antonelli F, Fernández M, Bravo P, Soto M, Cámara A, Torres F, Martí MJ; Catalan MSA Registry (CMSAR). Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophyParkinsonism Relat Disord. 2018 Jan;46:16-23.  


Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, EscottPrice V, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday GMHardy J, Trojanowski JQ, Dickson DW, Singleton A, Stone DJ, Bras J. Investigating the genetic architecture of dementia with Lewy bodies: a twostage genomewide association study. Lancet Neurol. 2018 Jan;17(1):64-74.